Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Uwm Research Foundation Inc. manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners across 2 distinct art units, showing a distributed prosecution landscape where each pending matter is subject to a different examiner's review. This structure suggests that the foundation's active biotechnology and pharmaceutical applications are being evaluated for separate technical merits, requiring a versatile approach to legal arguments across different examination teams.
The busiest examiner for the foundation is HAVLIN, ROBERT H, who is currently managing 1 pending office action. This represents one of the 2 pending office actions total for the company. The use of 2 distinct art units implies that the foundation must address the specific requirements of two different examination groups, as no single unit or examiner holds a majority of the current workload. This distribution requires the foundation to maintain a broad understanding of the various procedural standards applied within the biotechnology and pharmaceutical divisions of the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
| CHEONG, CHEOM-GIL | 1 | 64.1% | +53.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18855496 | DEUTERATED BENZODIAZEPINE ANALOGS AND METHODS OF USE IN TREATING CANCER | HAVLIN, ROBERT H | — |
| 18120799 | PSEUDOMONAS STRAINS AND THEIR METABOLITES TO CONTROL CITRUS HUANGLONGBING AND RELATED DISEASES | CHEONG, CHEOM-GIL | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18855496 | DEUTERATED BENZODIAZEPINE ANALOGS AND METHODS OF USE IN TREATING CANCER | HAVLIN, ROBERT H | 1626 | §103 | Non-Final OA | — | Pending | Oct 09, 2024 |
| 18120799 | PSEUDOMONAS STRAINS AND THEIR METABOLITES TO CONTROL CITRUS HUANGLONGBING AND RELATED DISEASES | CHEONG, CHEOM-GIL | 1645 | DP | Final Rejection | — | Pending | Mar 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUwm Research Foundation Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Robert H Havlin has the most, with 1 of Uwm Research Foundation Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
